Transmission and prevention

PrEP at CROI 2018 (part 1): Access in Australia and the US

PrEP at CROI 2018 (part 2): Animal studies for future drugs

London clinic to prescribe generic PrEP privately at £55 for 30 tablets

HIV in the UK 2017: a shift to eliminate AIDS

Update on PrEP IMPACT study – January 2018

PrEP use can reduce HIV stigma in gay communities

European HIV/AIDS surveillance report published (2017)

London signed up as a fast-track HIV city by Mayor Sadiq Khan

Screening HIV positive pregnant women for TB in South Africa increased detection by 10-fold

Updates from the PrEP IMPACT study – November 2017

New guides to PrEP

Featured The evidence for U=U (Undetectable = Untransmittable): why negligible risk is zero risk

New IPERGAY analysis shows on-demand PrEP dosing works with less frequent sex

On-demand dosing for PrEP is highly effective in French expanded access programme

Psychological impact of PrEP: beyond efficacy and cost-effectiveness

Early ART and testing HIV negative with rapid HIV tests

UK PrEP guidelines: online for comment

NHS access to PrEP in the UK: country update

Generic PrEP in France and Scotland challenges access across the UK

PrEP use in adolescent gay and bisexual men: US study shows need for easier access and easier PrEP

MK-8591: further compelling early results for both treatment and prevention

Gay men with undetectable viral load do not transmit HIV: Opposites Attract study supports U=U

Controversial PrEP study from NHS England due to start in September

HIV superinfection is associated with specific HLA types

New study of combined HIV prevention and contraception ring

Online video: PrEP 17 – The coming of age of PrEP

Drop in HIV incidence in gay men: frequent testing, early ART and PrEP

Potential for phylogenetic analysis to show direction of HIV transmission

Initiatives for earlier HIV diagnosis: opt-out ER and home testing

No new HIV cases in 398 people using PrEP at Dean Street clinic

PrEP in pregnancy does not increase poor birth outcomes

PrEP approved in Scotland but not in Wales

Acute infection with wild-type HIV on PrEP with good drug levels

Brighton heads towards zero HIV: first UK city with UN Fast Track status

Four London clinics report dramatic drops in HIV incidence in gay men: PrEP, early testing and early ART likely to be key

NHS England fudges PrEP access and delays on-demand access to PrEP by years; blocks doctors from prescribing PrEP now

Update on PrEP in Scotland

New York reports fewer HIV diagnoses in 2015: target to reduce new infections by 75% by 2020

UK Guide to PrEP (2nd Edition)

Generic PrEP bought online for UK use is validated by drug testing service

2nd HIV Research for Prevention Conference (HIVR4P) 2016, 17-20 October 2016, Chicago

A burgeoning PrEP pipeline: dozens of new drugs, formulations and delivery options

Second case of drug resistant HIV infection in person adherent on PrEP

TDF/FTC can be used as PrEP by breastfeeding mothers without risk to the baby

Potential for EFdA as PrEP to prevent HIV transmission in women and their infants

UK 2015 HIV statistics: high engagement with ART but new infections in gay men and late diagnosis overall still high

NHS England had no legal basis to delay PrEP: Court of Appeal upholds judgement

NICE evidence review supports efficacy of Truvada as PrEP in the UK

Fanconi-like lab abnormalities reported with daily PrEP: shows importance of routine kidney monitoring

Bone loss with PrEP in MSM aged 18-24

PrEP update: EU approval, extended access for PROUD participants, TAF studies underway

ZERO: no linked HIV transmissions in PARTNER study after couples had sex 58,000 times without condoms

ZERO HIV transmissions in PARTNER study: most widely reported i-Base article

PrEP studies at AIDS 2016: includes first preclinical data with EFdA

PROMISE results support WHO recommendations for pregnant and breastfeeding women: more needs to be done to improve ART acceptability and adherence

PROUD study closes leaving participants without access to PrEP

EMA overcomes its own prejudice to approve PrEP in Europe: four years too late

NAT legal challenge forces NHS England to reopen process for PrEP: 45-day public consultation now online

Two large PrEP studies using two-month infusion of antibodies to prevent HIV infection: oral PrEP included for all participants

Preventive technologies: antiretroviral and vaccine development

NHS England confuses arse and elbow: block to PrEP ignores UK HIV crisis and will send PEP services into chaos

Dramatic increase in use of oral TDF/FTC for PrEP in the US – plus a few cautions

Future oral and long-acting formulations for PrEP: pills, films, gels, injections and depots

First data on TAF as PrEP to prevent HIV infection

Long-acting cabotegravir as PrEP protects macaques against IV exposure but will need two-monthly injections

Post navigation